T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
Rana R. McKay,Rana R. McKay,Dominick Bossé,Wanling Xie,Stephanie A. Wankowicz,Abdallah Flaifel,Raphael Brandao,Aly-Khan A. Lalani,Dylan J. Martini,Xiao X. Wei,David A. Braun,Eliezer M. Van Allen,Daniel Castellano,Guillermo Velasco,J. Connor Wells,Daniel Y.C. Heng,Andre P. Fay,Fabio A.B. Schutz,JoAnn Hsu,Sumanta K. Pal,Jae-Lyun Lee,James J. Hsieh,Lauren C. Harshman,Sabina Signoretti,Robert J. Motzer,Darren R. Feldman,Toni K. Choueiri +26 more
TL;DR: Modest antitumor activity for PD-1/PD-L1–blocking agents was observed in some patients with nccRCC, and no specific genomic alteration was associated with clinical benefit.
Journal ArticleDOI
Recommendations for Post-Prostatectomy Radiation Therapy in the United States Before and After the Presentation of Randomized Trials
Karen E. Hoffman,Paul L. Nguyen,Ming-Hui Chen,Ronald C. Chen,Toni K. Choueiri,Jim C. Hu,Jim C. Hu,Deborah A. Kuban,Anthony V. D'Amico +8 more
TL;DR: Recommendations for post-prostatectomy radiation therapy did not increase after the initial reports from the randomized trials, perhaps because these studies initially reported improved biochemical disease-free survival but not overall survival.
Journal ArticleDOI
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
Elizabeth A. Guancial,Lillian Werner,Joaquim Bellmunt,Aristotle Bamias,Toni K. Choueiri,Robert S. Ross,Fabio A.B. Schutz,Rachel S. Park,Robert O'Brien,Michelle S. Hirsch,Justine A. Barletta,David M. Berman,Rosina T. Lis,Massimo Loda,Edward C. Stack,Levi A. Garraway,Markus Riester,Franziska Michor,Philip W. Kantoff,Jonathan E. Rosenberg,Jonathan E. Rosenberg +20 more
TL;DR: FGFR3 immunohistochemistry staining is present in one third of primary muscle‐invasive UCs and half of metastases, while FGFR3 mutations and copy number changes are relatively uncommon.
Journal ArticleDOI
LBA5CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups
Bernard Escudier,Nizar M. Tannir,David F. McDermott,O.A. Frontera,Bohuslav Melichar,Elizabeth R. Plimack,Philippe Barthélémy,Saby George,Victoria Neiman,C. Porta,Toni K. Choueiri,Thomas Powles,Frede Donskov,P. Salman,Christian K. Kollmannsberger,Brian I. Rini,Sabeen Mekan,M.B. McHenry,Hans J. Hammers,Robert J. Motzer +19 more
Journal ArticleDOI
Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Sumanta K. Pal,Siraj M. Ali,Evgeny Yakirevich,Daniel M. Geynisman,Jose A. Karam,Julia A. Elvin,Garrett M. Frampton,Xuan Huang,Douglas I. Lin,Margaret Rosenzweig,Doron Lipson,Philip J. Stephens,Jeffrey S. Ross,Vincent A. Miller,Neeraj Agarwal,Brian Shuch,Toni K. Choueiri,Jon Chung +17 more
TL;DR: The frequency of genomic alterations (GAs) in patients with advanced PRCC for whom comprehensive genomic profiling was performed in the context of routine clinical care is characterized to inform planned precision medicine trials for metastatic PRCC.